Get the Stockscreener App
36.34
0.03%
0.01
Pacira Biosciences Inc stock is traded at $36.34, with a volume of 960.89K.
It is up +0.03% in the last 24 hours and up +45.89% over the past month.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
See More
Previous Close:
$36.33
Open:
$36.38
24h Volume:
960.89K
Relative Volume:
0.21
Market Cap:
$1.45B
Revenue:
$734.86M
Net Income/Loss:
$5.14M
P/E Ratio:
290.72
EPS:
0.125
Net Cash Flow:
$132.71M
1W Performance:
+0.08%
1M Performance:
+45.89%
6M Performance:
+52.31%
1Y Performance:
+59.60%
1-Day Range:
$36.32
$36.39
1-Week Range:
$36.30
$36.66
52-Week Range:
$18.80
$36.66
Pacira Biosciences Inc Stock (PCRX) Company Profile
Name
Pacira Biosciences Inc
Sector
Phone
650-242-8052
Address
2000 SIERRA POINT PARKWAY, BRISBANE, NJ
Compare PCRX vs TAK, TEVA, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PCRX
Pacira Biosciences Inc
|
36.34 | 1.45B | 734.86M | 5.14M | 132.71M | 0.125 |
TAK
Takeda Pharmaceutical Co Adr
|
19.67 | 62.84B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
41.50 | 48.40B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
10.13 | 44.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
79.38 | 32.80B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
533.12 | 22.87B | 3.17B | 1.29B | 1.01B | 27.09 |
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-23-26 | Initiated | Oppenheimer | Outperform |
| Sep-09-26 | Initiated | Leerink Partners | Market Perform |
| Aug-17-26 | Resumed | Truist | Buy |
| Dec-09-25 | Initiated | Barclays | Equal Weight |
| Nov-17-25 | Initiated | H.C. Wainwright | Buy |
| Jul-25-25 | Upgrade | Truist | Hold → Buy |
| Jan-30-25 | Upgrade | Truist | Sell → Hold |
| Aug-13-24 | Downgrade | Truist | Buy → Sell |
| Aug-12-24 | Downgrade | JP Morgan | Overweight → Underweight |
| Aug-12-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-12-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-12-24 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jul-03-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-07-24 | Resumed | JP Morgan | Overweight |
| Dec-20-23 | Initiated | Raymond James | Outperform |
| Aug-03-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Jan-31-23 | Resumed | Wedbush | Outperform |
| Oct-21-22 | Resumed | Jefferies | Buy |
| Jan-03-22 | Resumed | JP Morgan | Overweight |
| Jul-26-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-21-21 | Resumed | JP Morgan | Neutral |
| Apr-09-21 | Initiated | Berenberg | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-11-21 | Downgrade | Northland Capital | Outperform → Market Perform |
| Jan-21-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-21-20 | Upgrade | Northland Capital | Market Perform → Outperform |
| Jul-06-20 | Reiterated | Needham | Buy |
| May-27-20 | Initiated | Guggenheim | Neutral |
| Apr-07-20 | Initiated | Northland Capital | Outperform |
| Mar-20-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Feb-24-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-24-20 | Initiated | SunTrust | Buy |
| Jan-23-20 | Initiated | SunTrust | Buy |
| Nov-06-19 | Initiated | BTIG Research | Buy |
| Jun-11-19 | Initiated | Barclays | Overweight |
| May-06-19 | Upgrade | Mizuho | Underperform → Neutral |
| May-02-19 | Upgrade | Stifel | Sell → Hold |
| Feb-01-19 | Downgrade | Mizuho | Neutral → Underperform |
| Aug-06-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Apr-09-18 | Reiterated | H.C. Wainwright | Buy |
| Mar-21-18 | Reiterated | Mizuho | Neutral |
| Feb-16-18 | Downgrade | Needham | Buy → Hold |
| Jan-19-18 | Initiated | Seaport Global Securities | Buy |
| Jan-04-18 | Reiterated | Canaccord Genuity | Buy |
| Jan-03-18 | Initiated | Leerink Partners | Mkt Perform |
View All
Pacira Biosciences Inc Stock (PCRX) Latest News
Seven investors report stakes below 5% in Pacira BioSciences (PCRX). - Stock Titan
Form 4 Pacira Pharmaceuticals Inc For: 12 October By Investing.com - Investing.com South Africa
Pacira BioSciences SVP Riker sells $217,920 stock - Investing.com
Pacira BioSciences SVP Riker sells $217,920 stock By Investing.com - Investing.com Canada
Pacira BioSciences SVP Lauren Riker sells $217,920 in stock - Investing.com
Form 4 Pacira Pharmaceuticals Inc For: 10 October By Investing.com - Investing.com South Africa
Pacira BioSciences SVP Lauren Riker sells $217,920 in stock - Investing.com
Form 4 Pacira Pharmaceuticals Inc For: 9 October By Investing.com - Investing.com South Africa
Pacira BioSciences senior vice president Lauren Riker sells $217,920 in stock By Investing.com - Investing.com South Africa
Form 4 Pacira Pharmaceuticals Inc For: 9 October By Investing.com - Investing.com Nigeria
Pacira BioSciences senior vice president Lauren Riker sells $217,920 in stock - Investing.com
After exercising options, Lauren Riker sells 6,000 Pacira BioSciences (PCRX) shares. - Stock Titan
Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio - Zacks Investment Research
Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio - TradingView
An offer for all Pacira BioSciences (PCRX) shares is planned but has not yet begun. - Stock Titan
No financing condition applies to the planned Viatris takeover of Pacira BioSciences (PCRX). - Stock Titan
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Pacira BioSciences (Nasdaq: PCRX) Makes 52 Week High on Acquisition News - Investorideas.com
Viatris Inc. entered into a definitive agreement to acquire Pacira BioSciences, Inc. for $1.6 billion. - marketscreener.com
Viatris to Acquire Pacira BioSciences for $36.50 Per Share in $1.65 Billion Cash Deal - Minichart
Why Pacira BioSciences Skyrocketed Today - The Motley Fool
Viatris Acquires Pacira BioSciences for $1.65 Billion - Pharmaceutical Executive
A 6,000-share sale is proposed by Lauren B. Riker of Pacira BioSciences (PCRX). - Stock Titan
With unanimous board backing, Pacira (PCRX) agrees to an all-cash Viatris takeover. - Stock Titan
Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies - Viatris Newsroom
Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies - PR Newswire
PCRX Expands Exparel Commercial Reach in Europe Through Molteni Deal - Zacks Investment Research
Pacira Announces Exclusive Agreement with Molteni Farmaceutici to Commercialize EXPAREL® in the European Union and United Kingdom - Orthopedics This Week
A postsurgery pain medicine is planned to launch in four countries; first sales are expected in 2027. - Stock Titan
Discipline and Rules-Based Execution in PCRX Response - Stock Traders Daily
Pacira Biosciences (NASDAQ:PCRX): An Undervalued Value Stock Backed by Cash Flow and Balance Sheet Strength - ChartMill
PACIRA BIOSCIENCES, INC. : LEERINK PARTNERS INITIATES COVERAGE WITH MARKET PERFORM RATING; PRICE TARGET $28 - webull.com
PCRX Initiated Coverage by Leerink Partners -- Rating Market Per - GuruFocus
Five new employees receive Pacira stock awards, vesting over four years - Stock Titan
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Pacira (PCRX) Up 6.9% Since Last Earnings Report: Can It Continue? - Yahoo Finance
(PCRX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Pacira BioSciences stock update with limited verified data - ad-hoc-news.de
Truist Financial Initiates Pacira BioSciences(PCRX.US) With Buy Rating - Moomoo
Pacira BioSciences Inc (PCRX) Stock Up 3.5% and Still Undervalued -- GF Score: 81/100 - GuruFocus
Foster & Motley Inc. Buys New Holdings in Pacira BioSciences, Inc. $PCRX - MarketBeat
Pacira (PCRX) Q2 2026 Results: Reported EPS Tops Expectations in Latest Trading; Post-Earnings: The Stock Gains 1.67% for the Current SessionBalance Sheet Strength - vinanet.vn
Rice Hall James & Associates LLC Purchases Shares of 93,396 Pacira BioSciences, Inc. $PCRX - MarketBeat
Pacira BioSciences Inc (PCRX) Chief Medical Officer Jonathan Slo - GuruFocus
Pacira BioSciences (NASDAQ:PCRX) Insider Jonathan Slonin Sells 3,040 Shares of Stock - MarketBeat
Pacira BioSciences (PCRX) CMO sells 3,040 shares in 10b5-1 plan - Stock Titan
Pacira (PCRX) Daily Price Brief: Records a 2.17% Increase to $23.75 in Latest Trading; Technical Focus: $22.56 and $24.94 Define the Nearby Reference Levels on the DayBPI Bull Correction - vinanet.vn
Pacira BioSciences (NASDAQ: PCRX) faces $70.6K share sale in 2026 - Stock Titan
Pacira BioSciences (NASDAQ:PCRX) Coverage Initiated at Truist Financial - MarketBeat
Truist Financial Upgrades Pacira BioSciences(PCRX.US) to Buy Rating, Raises Target Price to $30 - Moomoo
Pacira Biosciences Inc Stock (PCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Pacira Biosciences Inc Stock (PCRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| RIKER LAUREN | Senior Vice President, Finance |
Oct 08 '26 |
Sale |
36.32 |
6,000 |
217,920 |
62,284 |
| RIKER LAUREN | Officer |
Oct 08 '26 |
Proposed Sale |
36.32 |
6,000 |
217,920 |
0 |
| SLONIN JONATHAN | Chief Medical Officer |
Aug 17 '26 |
Sale |
23.23 |
3,040 |
70,619 |
216,384 |
| SLONIN JONATHAN | Officer |
Aug 17 '26 |
Proposed Sale |
23.23 |
3,040 |
70,619 |
0 |
| Ceesay Abraham | Director |
Jun 12 '26 |
Proposed Sale |
23.27 |
9,039 |
210,374 |
0 |
| RIKER LAUREN | Senior Vice President, Finance |
Jun 11 '26 |
Sale |
23.50 |
6,115 |
143,702 |
62,284 |
| RIKER LAUREN | Officer |
Jun 11 '26 |
Proposed Sale |
23.50 |
6,115 |
143,702 |
0 |
| WILLIAMS KRISTEN | Chief Administrative Officer |
Jun 04 '26 |
Sale |
22.27 |
10,259 |
228,468 |
167,062 |
| WILLIAMS KRISTEN | Officer |
Jun 04 '26 |
Proposed Sale |
22.27 |
10,259 |
228,468 |
0 |
| Cross Shawn | Chief Financial Officer |
Apr 23 '26 |
Option Exercise |
16.45 |
12,941 |
212,879 |
118,282 |
1.99%
2.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):